gotistobart

all catalysts(0)

nothing on the calendar yet

News(4)

• BioNTech says CTLA-4 drug nearly doubled survival times for lung cancer
  BioNTech delivered a compelling piece of evidence Monday supporting the development of its CTLA-4 antibody gotistobart in lung cancer. Previously treated lung cancer patients who received the CTLA-…
  endpoints · 20d ago
• Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
  BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place in South Korea. These companies and their partners have all shared new fi…
  biospace · 20d ago
• BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
  BioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
  fiercebiotech · 23d ago
• After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
  One of the most closely watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.
  fiercebiotech · 2mo ago